Sector: Health Care
Director information for INDIVIOR PHARMACEUTICALS INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Barbara Ryan | Independent Non-Executive Director | 66 | ["financial", "investment", "capital markets", "M&A", "valuation", "SEC reporting", "financial analysis", "corporate strategy"] | ["Audit", "Compensation", "Compliance & Ethics", "Nominating & Corporate Governance", "Nominating & Corporate Governance Committee"] | 2026 |
| Christian Heidbreder | Chief Scientific Officer | 63 | ["over 35 years of experience in the neurosciences", "authored more than 500 peer-reviewed publications", "former Governance Fellow of the National Association of Corporate Directors", "served on the National Advisory Council on Drug Abuse", "served on the NIH\u2019s HEAL Multi-Disciplinary Working Group"] | [] | 2026 |
| Daniel Ninivaggi | Independent Non-Executive Director; Chair | 61 | ["executive management", "investment", "global business", "legal", "corporate governance", "strong leadership skills"] | ["Audit", "Compensation", "Nominating & Corporate Governance", "Nominating & Corporate Governance Committee"] | 2026 |
| David Wheadon | Independent Chair | 68 | ["Medical", "Scientific", "Regulatory Affairs"] | ["Audit", "Compensation", "Compliance & Ethics", "Nominating & Corporate Governance", "Science", "Science Committee"] | 2026 |
| Joe Ciaffoni | Executive Director and Chief Executive Officer | 55 | ["Senior Executive in Pharmaceutical Industry", "Operations", "Board Experience"] | [] | 2026 |
| Juliet Thompson | Non-Executive Director | 59 | ["Over 30 years of finance, banking, and board experience", "Proven FTSE 250 audit chair", "Former investment banker advising pharmaceutical and biotech companies", "BSc in Economics from the University of Bristol", "Chartered Accountant holding an ACA from the Association of Chartered Certified Accountants"] | ["Audit", "Compensation", "Audit (Chair)", "Compliance & Ethics", "Nominating & Corporate Governance", "Compliance & Ethics Committee", "Nominating & Corporate Governance Committee"] | 2026 |
| Keith Humphreys | Non-Executive Director; Chair | 59 | ["Esther Ting Memorial Professor in the Department of Psychiatry and Behavioral Sciences at Stanford University", "Senior Policy Advisor in the White House Office of National Drug Control Policy in the Obama Administration", "Honorary Professor of Psychiatry at the Institute of Psychiatry, King\u2019s College, London", "Officer of the Order of the British Empire (OBE) for services to science and policy on addiction", "BA in Psychology from Michigan State University", "AM in Clinical/Community Psychology and PhD in Psychology from the University of Illinois"] | ["Compliance & Ethics", "Science (Chair)", "Compliance & Ethics Committee", "Science Committee"] | 2026 |
| Mark Stejbach | Non-Executive Director; Chair | 62 | ["Over 35 years of experience in the biotech and pharmaceutical industries", "Former Senior Vice President & Chief Commercial Officer at Alkermes plc", "Held senior positions at Merck & Co. Inc. and Biogen Inc.", "MBA from the Wharton School, University of Pennsylvania", "BS in mathematics from Virginia Tech"] | ["Audit", "Compliance & Ethics (Chair)", "Science", "Compliance & Ethics Committee", "Science Committee"] | 2026 |
| Pat Barry | Chief Commercial Officer | 58 | ["proven commercial leader", "more than 30 years of experience in the pharmaceutical, biotech, and medical device industries", "strong track record of building high-performing teams", "galvanizing organizations around a shared purpose"] | [] | 2026 |
| Tony Kingsley | Non-Executive Director | 62 | ["Accomplished biopharmaceutical executive with a distinguished track record", "CEO and Director of Stablix, Inc.", "President, CEO and executive director of Scholar Rock Holding Corp.", "Led TARIS Biomedical LLC as President and CEO", "President and Chief Operating Officer at The Medicines Company", "Executive Vice President of Global Commercial Operations at Biogen Inc.", "Partner at McKinsey & Company", "Graduated magna cum laude from Dartmouth College", "MBA from Harvard Business School"] | ["Audit", "Compensation"] | 2026 |
